Oral Transglutaminase 2 Inhibitor Beneficial in Celiac Disease The primary end point in the study was attenuation of gluten-induced mucosal damage. (Credit: Getty Images.)
HealthDay News â For patients with celiac disease, treatment with a selective oral transglutaminase 2 inhibitor (ZED1227) attenuates gluten-induced duodenal mucosal damage, according to a study published in the July 1 issue of the
New England Journal of Medicine.
Detlef Schuppan, MD, PhD, from the Johannes Gutenberg University in Mainz, Germany, and colleagues conducted a proof-of-concept trial of a 6-week treatment with ZED1227 at 3 dose levels vs placebo among adults with well-controlled celiac disease who underwent a daily gluten challenge. The primary end point of attenuation of gluten-induced mucosal damage was assessed among 35, 39, 38, and 30 patients assigned to 10-, 50-, and 100mg ZED1227 and placebo, respectively.
Celiac Disease: Novel Oral Inhibitor May Block Intestinal Damage
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Oral Transglutaminase 2 Inhibitor Beneficial in Celiac Disease
physiciansweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from physiciansweekly.com Daily Mail and Mail on Sunday newspapers.
Eruption of Laacher See volcano redated
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.